Products for Research Use Only

(S) -JQ-35

CAT: 0804-HY-117286-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-117286-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
(S) -JQ-35 (TEN-010) is a selective bromodomain and extra-terminal domain (BET) protein family inhibitor targeting BRD4, BRD3, BRD2 and BRDT. (S) -JQ-35 is orally active and can penetrate the blood-brain barrier. (S) -JQ-35 competitively binds to the bromodomain of BRD4, preventing it from binding to the Myc gene promoter, thereby inhibiting cancer cell proliferation and inducing cell apoptosis. (S) -JQ-35 can be used for targeted therapy research of malignant tumors such as NUT midline carcinoma and refractory solid tumors[1][2].
CAS Number
1349719-98-7
Product Name Alternative
TEN-010
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
Apoptosis; Epigenetic Reader Domain
Type
Reference compound
Related Pathways
Apoptosis; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/JQ-35,__S_-.html
Purity
99.46
Solubility
DMSO : ≥ 85 mg/mL
Smiles
O=C(NCCCN1CCN(C)CC1)C[C@H]2C3=NN=C(C)N3C4=C(C(C)=C(C)S4)C(C5=CC=C(Cl)C=C5)=N2
Molecular Formula
C27H34ClN7OS
Molecular Weight
540.12
Precautions
H302, H315, H319
References & Citations
[1]Samples S, et al. Intrapericardial NUT Midline Carcinoma: Unusual Presentation of a Rare Tumor and Literature Review with Management Considerations. Pediatr Cardiol. 2016 Jan;37 (1) :208-11.|[2]Sharifi Z, et al. Pharmacokinetics of ZR2002, a combi-molecule with EGFR and DNA-damaging properties and its efficacy in an orthotopic glioblastoma mouse model[J]. Annals of Oncology, 2018, 29: iii12.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1